Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 21, 2026Lung Cancer

Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification

View Full Paper
Ask AI
Bookmark
Share

Authors

LYLin-Xi YinZHZi-Jian HuangLWLv Wu

Discussion

Loading...

Member takes

Overview

Retrospective study shows second-generation EGFR TKIs improve outcomes in EGFR mutant non-small cell lung cancer, suggesting prognostic roles of EGFR amplification.

Key Points

  • This research aims to evaluate the impact of EGFR amplification on treatment outcomes in EGFR-mutant non-small cell lung cancer (NSCLC).
  • Retrospective study of 781 patients with advanced EGFR-mutant NSCLC
  • Patients stratified by EGFR amplification status
  • Survival outcomes analyzed using Kaplan-Meier and multivariate Cox models
  • Subgroup analyses based on EGFR mutation type and TKI generation
  • Patients with co-occurring EGFR amplification had a trend toward shorter OS compared to EGFR mutation alone (37.3 vs. 32.7 months)
  • EGFR L858R subgroup showed significantly shorter median PFS with amplification (8.9 vs. 12.4 months)
  • Second-generation TKIs exhibited better PFS (11.1 vs. 7.0 months) and OS (32.4 vs. 15.4 months) than third-generation TKIs

Cite This Study

Yin et al. (2026) studied this question.

synapsesocial.com/papers/69990e0a5b97ab4c14ac317bhttps://doi.org/10.1016/j.lungcan.2026.109339
View Full Paper
Ask AI
Bookmark
Share